Investigation of Carbapenemase-Producing Pseudomonas aeruginosa at Secondary Care Hospital in Bolu, Turkey
Microbial Drug Resistance · 2024
DOI: 10.1089/mdr.2024.0067 ↗Kurz gefasst
Fachartikel in der Zeitschrift Microbial Drug Resistance, 2024. Verfasst von Zuhal Kalaycı Çekin und 2 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Microbiology Laboratory, Bolu Izzet Baysal State Hospital, Bolu, Turkey. Hauptthemen laut MEDLINE: beta-Lactamases, Pseudomonas aeruginosa, Bacterial Proteins, Anti-Bacterial Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 38 Literaturangaben.
Abstract (Originalsprache)
The global increase in carbapenem resistance poses a significant public health threat due to the potential emergence of multidrug-resistant pathogens and limited treatment options. To learn more about this issue and offer potential solutions, we conducted a study of carbapenem-resistant Pseudomonas aeruginosa (CRPA) infections in a secondary care hospital setting. The study utilized the carbapenem inactivation method (CIM), a leading phenotypic analysis, to determine carbapenemase activity in 63 CRPA isolates. Additionally, polymerase chain reaction (PCR) analysis was conducted to test for the presence of carbapenemase genes associated with the production or expression of various carbapenemase enzymes, including bla KPC , bla NDM , bla VIM , bla OXA-48 , bla IMP , and bla GES . Arbitrary primed PCR (AP-PCR) was performed to assess the clonal relationship between different isolates. The isolates were also classified as either health care-associated infections or community-acquired infections, and their clonal relationship and gene positivity were evaluated. A total of 63 CRPA samples underwent evaluation, with 14 isolates determined to be carbapenemase producers via CIM tests. PCR assays revealed that 14 isolates carried carbapenemase genes, with 9 carrying bla NDM , 2 carrying bla GES , 2 carrying bla VIM , and 1 carrying bla IMP . CRPA exhibited a 22% prevalence of carbapenemase genes, of which 64% were attributed to the NDM gene responsible for multidrug resistance. AP-PCR revealed high clonal diversity among the isolates. Molecular epidemiological evaluation also showed no dominant outbreak strain among PA isolates. This study presents significant data on the prevalence and distribution of carbapenemase-producing CRPA strains isolated from secondary health care facilities. Typically, the literature focuses on resistance rates in tertiary care public hospitals. These findings may aid in understanding resistance and its mechanisms, as well as in developing effective treatment strategies and infection control measures.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Clinical Microbiology Laboratory, Bolu Izzet Baysal State Hospital, Bolu, Turkey.
- Department of Medical Microbiology, Inonu University Faculty of Medicine, Molecular Microbiology Laboratory, Inonu University Turgut Ozal Medical Centre, Malatya, Turkey.
ORCID-Profile: Zuhal Kalaycı Çekin
Zitieren
APA
Kalaycı Çekin, Z., Tanrıverdi, E. S., & Otlu, B. (2024). Investigation of Carbapenemase-Producing Pseudomonas aeruginosa at Secondary Care Hospital in Bolu, Turkey. Microbial Drug Resistance. https://doi.org/10.1089/mdr.2024.0067
Vancouver
Kalaycı Çekin Z, Tanrıverdi ES, Otlu B. Investigation of Carbapenemase-Producing Pseudomonas aeruginosa at Secondary Care Hospital in Bolu, Turkey. Microbial Drug Resistance. 2024. doi:10.1089/mdr.2024.0067
BibTeX
@article{Kalaycekin2024,
author = {Kalaycı Çekin, Zuhal and Tanrıverdi, Elif Seren and Otlu, Barış},
title = {Investigation of Carbapenemase-Producing Pseudomonas aeruginosa at Secondary Care Hospital in Bolu, Turkey},
journal = {Microbial Drug Resistance},
year = {2024},
doi = {10.1089/mdr.2024.0067}
}
EUVIMED